Cargando…
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
INTRODUCTION: Focal segmental glomerulosclerosis (FSGS), a histologic lesion in the kidney caused by varied pathophysiological processes, leads to end-stage kidney disease in a large proportion of patients. Sparsentan is a first-in-class orally active compound combining endothelin type A (ET(A)) rec...
Autores principales: | Komers, Radko, Diva, Ulysses, Inrig, Jula K., Loewen, Andrea, Trachtman, Howard, Rote, William E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136327/ https://www.ncbi.nlm.nih.gov/pubmed/32274453 http://dx.doi.org/10.1016/j.ekir.2019.12.017 |
Ejemplares similares
-
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
por: Trachtman, Howard, et al.
Publicado: (2023) -
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
por: Komers, Radko, et al.
Publicado: (2017) -
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023) -
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis
por: Wada, Russell, et al.
Publicado: (2023) -
Complement Activation in Patients with Focal Segmental Glomerulosclerosis
por: Thurman, Joshua M., et al.
Publicado: (2015)